<DOC>
	<DOCNO>NCT00667732</DOCNO>
	<brief_summary>This study design look use glargine insulin oral diabetes medication exenatide may improve control blood sugar level weight gain type 2 diabetic . The main study last 32 week . However , participant complete 32 week invite continue another 24 week take insulin oral medication exenatide treatment . This extension compare insulin oral medication insulin oral medication exenatide look long term weight loss/gain blood sugar level control effect new drug regimen . There also sub-study Clinical Research Center ( CRC ) , require two 38-hour inpatient stay main study . This study offer opportunity study 24-hour blood sugar metabolic pattern quantitatively .</brief_summary>
	<brief_title>How Glargine Insulin , Oral Diabetes Medications Exenatide May Improve Blood Sugar Control Weight Gain Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female patient type 2 diabetes Taking metformin least 1000 mg daily plus secretagogue , alpha glucosidase inhibitor , thiazolidinedione , single injection kind insulin 0.4 units/kg daily &gt; 3 month Age range 30 70 year Body mass index 2545 kg/m2 HbA1c 7.0 10.0 % ( 7.0 8.5 % second antihyperglycemic agent insulin ) Less 50 % randomized participant use insulin previously Use two antihyperglycemic agent within last 3 month Use one daily injection kind insulin last 3 month Positive antiGAD antibody ( test require screening ) Fasting Cpeptide &lt; 0.5 ng/mL ( test require screening ) Pregnancy ( test require screen able conceive ) lactation Excessive use alcohol evidence form drug dependency Unwillingness inability grant inform consent Unwillingness inability perform selfmonitoring blood glucose Unwillingness inability inject insulin and/or inject exenatide Serum creatinine &gt; 1.3 mg/dL woman 1.4 men Retinopathy require photocoagulation treatment Major active systemic illness ( e.g . neoplastic disorder , symptomatic ischemic heart disease , congestive heart failure ) might interfere perform study protocol Clinically significant gastrointestinal disorder include prior gastric intestinal surgery weightcontrol Ongoing use drug ( e.g . narcotic analgesic , tricyclic antidepressant ) might alter gastric emptying Use prednisone systemic glucocorticoid drug last 3 month Use drug weightcontrol ( e.g . sibutramine , phentermine , orlistat ) last 3 month Use unproven investigational drug within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin</keyword>
	<keyword>byetta</keyword>
	<keyword>glucose</keyword>
	<keyword>blood sugar</keyword>
	<keyword>metformin</keyword>
	<keyword>A1c</keyword>
</DOC>